The UK government has committed £100 million to establish a centre to scale up COVID-19 vaccine and gene therapy manufacturing.
List view / Grid view
Cell and Gene Therapy Catapult
Filter the results
New research has found that the cell and gene therapy clinical environment in the UK has encouraged commercial sponsorship from around the world.
An additional 6,000m2 of cell and gene therapy manufacturing space is expected to become available within the next 12 months, according to new data.
14 April 2016 | By Victoria White, Digital Content Producer
The Cell and Gene Therapy Catapult has announced a positive interim review of a Phase I/II trial using WT1-TCR t-cell therapy to target acute myeloid leukaemia...